Tags

Type your tag names separated by a space and hit enter

Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis.
Arch Med Res. 2012 Jul; 43(5):356-62.AM

Abstract

BACKGROUND AND AIMS

We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA).

METHODS

The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD).

RESULTS

Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I(2) = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance.

CONCLUSIONS

This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA.

Authors+Show Affiliations

Department of Internal Medicine, Division of Rheumatology, Korea University College of Medicine, Seoul, Korea. lyhcgh@korea.ac.krNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22835600

Citation

Lee, Young-Ho, et al. "Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis: a Meta-analysis." Archives of Medical Research, vol. 43, no. 5, 2012, pp. 356-62.
Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res. 2012;43(5):356-62.
Lee, Y. H., Bae, S. C., & Song, G. G. (2012). Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Archives of Medical Research, 43(5), 356-62. https://doi.org/10.1016/j.arcmed.2012.06.011
Lee YH, Bae SC, Song GG. Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis: a Meta-analysis. Arch Med Res. 2012;43(5):356-62. PubMed PMID: 22835600.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. AU - Lee,Young-Ho, AU - Bae,Sang-Cheol, AU - Song,Gwan-Gyu, Y1 - 2012/07/24/ PY - 2012/02/14/received PY - 2012/06/06/accepted PY - 2012/7/28/entrez PY - 2012/7/28/pubmed PY - 2013/2/6/medline SP - 356 EP - 62 JF - Archives of medical research JO - Arch Med Res VL - 43 IS - 5 N2 - BACKGROUND AND AIMS: We undertook this study to assess the effects of omega-3 polyunsaturated fatty acids (PUFAs) (administered at ≥2.7 g/day) for a minimum duration of 3 months on clinical outcomes in patients with rheumatoid arthritis (RA). METHODS: The authors surveyed randomized controlled trials (RCTs) that examined the effects of omega-3 PUFAs on clinical outcomes in RA patients using Medline and the Cochrane Controlled Trials Register and by performing manual searches. Meta-analysis of RCTs was performed using fixed and random effects models. Outcomes are presented as standardized mean differences (SMD). RESULTS: Ten RCTs involving 183 RA patients and 187 placebo-treated RA controls were included in this meta-analysis. The analysis showed that omega-3 PUFAs clearly reduced nonsteroidal anti-inflammatory drug (NSAID) consumption (SMD -0.518, 95% CI -0.915 to -0.121, p = 0.011) without between-study heterogeneity (I(2) = 0%). Tender joint count (SMD -0.214, 95% CI-0.489-0.062, p = 0.128), swollen joint count (SMD -0.170, 95% CI-0.454-0.114, p = 0.241), morning stiffness (SMD -0.224, 95% CI-0.955-0.212, p = 0.221), and physical function (SMD 0.264, 95% CI-0.232-0.724, p = 0.314) showed a trend to improve more in patients treated with omega-3 PUFAs than in placebo-treated controls, but they did not reach statistical significance. CONCLUSIONS: This meta-analysis suggests that the use of omega-3 PUFAs at dosages >2.7 g/day for >3 months reduces NSAID consumption by RA patients. Further studies are needed to explore the clinical and NSAID-sparing effects of omega-3 PUFAs in RA. SN - 1873-5487 UR - https://www.unboundmedicine.com/medline/citation/22835600/Omega_3_polyunsaturated_fatty_acids_and_the_treatment_of_rheumatoid_arthritis:_a_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0188-4409(12)00166-X DB - PRIME DP - Unbound Medicine ER -